SMA Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-294
Closed -$11.8K – 124
2026
Q1
$11.8K Buy
+294
New +$6.33K 0.01% 66

Other funds holding APLS

SMA Capital's APLS Position: Q2 2026 in Review

SMA Capital sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 294 shares — an estimated $11.8K sold.

SMA Capital first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $11.8K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • SMA Capital reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • SMA Capital sold 294 Apellis Pharmaceuticals shares in Q2 2026, an estimated $11.8K.
  • SMA Capital first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • SMA Capital's Apellis Pharmaceuticals position peaked at $11.8K in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on SMA Capital's 13F filing for Q2 2026, filed 14 Aug 2026.